The debate highlighted that G2019S shows elevated baseline RAB10 phosphorylation, but it's unclear whether this represents true signal amplification during lysosomal swelling or just a higher activity floor. This distinction is crucial for understanding disease mechanisms and therapeutic targeting.
Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867_20260416-135352 (Analysis: SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867)
G2019S causes elevated baseline RAB10 phosphorylation via chronic ER stress pathway (PERK/eIF2α) unrelated to lysosomal volume-sensing. True signal amplification is pathogenic; baseline elevation is compensatory. PERK inhibitor GSK2606414 can test whether baseline elevation depends on ER stress in both genotypes.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["ER Stress Unfolded Protein Response"]
B["PERK Activation Kinase"]
C["eIF2alpha Phosphorylation"]
D["Integrated Stress Response (ISR)"]
E["Synaptic Protein Translation Suppression"]
F["LRRK2 Mutation G2019S"]
G["Lysosomal Dysfunction"]
H["Neuronal Death"]
A --> B
B --> C
C --> D
D --> E
F --> G
G --> H
E --> H
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
4 citations4 with PMIDValidation: 0%2 supporting / 2 opposing
✓For(2)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
MECH 4CLIN 0GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
LRRK2 G2019S induces ER stress in dopaminergic neu…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Therapeutic/Mechanistic Hypotheses Addressing LRRK2 Signal Amplification vs. Baseline Elevation
Hypothesis 1: G2019S Acts as a Lysosomal Volume-Sensing Amplifier via Enhanced RAB29-Dependent Recruitment
Mechanism: G2019S specifically hyperactivates LRRK2 when recruited to swelling lysosomes via RAB29, creating a pathogenic positive feedback loop where membrane stress increases RAB10 phosphorylation more than wild-type.
Target Gene/Protein: LRRK2 (G2019S) + RAB29 axis
Supporting Evidence:
RAB29 pathogenic mutations (PARK23) cause early-onset Parkinsonism (PMID: 28165
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of LRRK2 Hypotheses
Overview
The core question—whether G2019S increases signal amplification during lysosomal swelling versus merely elevating the baseline activity floor—requires distinguishing between these mechanistically distinct possibilities. Most hypotheses conflate these, and none provide decisive evidence for either model.
Hypothesis 1: Lysosomal Volume-Sensing Amplifier via RAB29
Weak Links
Recruitment enhancement not demonstrated: The cited PMIDs establish that RAB29 recruits LRRK2 to stressed lysosomes, but do not show G2019S specifica
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Feasibility Assessment: LRRK2 G2019S Signal Amplification vs. Baseline Elevation Hypotheses
Executive Summary
The core mechanistic question—whether LRRK2 G2019S drives pathology through amplified signaling during lysosomal stress versus simply elevating the basal activity floor—carries significant therapeutic implications. If amplification is pathogenic, partial kinase inhibition strategies become rational; if elevated baseline alone drives neurodegeneration, complete inhibition may be required. This distinction will shape trial design, dose selection, and acceptable safety profiles.
B
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
IF human iPSC-derived dopaminergic neurons carrying G2019S LRRK2 are treated with 1 μM GSK2606414 (PERK inhibitor) for 24 hours, THEN baseline p-T72 RAB10 will decrease by ≥50% compared to vehicle-treated G2019S neurons within 48 hours of compound addition.
pendingconf: 0.75
Expected outcome: Significant reduction in RAB10 phosphorylation at baseline in G2019S neurons following PERK inhibition, with no change in total RAB10 protein levels
Falsified by: GSK2606414 treatment fails to reduce baseline p-T72 RAB10 levels in G2019S neurons below 75% of vehicle control, indicating baseline elevation is independent of PERK/eIF2α signaling
Method: Immunoblotting or phospho-specific SIMOA assay for p-T72 RAB10 in iPSC-derived dopaminergic neurons from ≥3 G2019S LRRK2 carriers and ≥3 isogenic controls, treated with GSK2606414 vs. DMSO vehicle
IF baseline RAB10 phosphorylation is normalized by 72-hour PERK inhibition and neurons are then challenged with 20 μM chloroquine for 2 hours, THEN the relative fold-increase in p-T72 RAB10 will be identical (±20%) between GSK2606414-pretreated G2019S neurons and vehicle-pretreated G2019S neurons.
pendingconf: 0.65
Expected outcome: Lysosomal stress-induced RAB10 phosphorylation amplification remains intact after PERK blockade, demonstrating pathway independence from chronic ER stress
Falsified by: GSK2606414 pretreatment abolishes or reduces the chloroquine-induced RAB10 phosphorylation increase by >50% in G2019S neurons, disproving the hypothesis that lysosomal amplification is mechanistically distinct from ER stress-dependent baseline elevation
Method: Sequential treatment protocol: iPSC-derived dopaminergic neurons (G2019S) pretreated with GSK2606414 or vehicle for 72h, followed by chloroquine challenge; p-T72 RAB10 quantified by immunoblot or targeted MS, normalized to β-actin loading control
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
PERK — Search for structure
Click to search RCSB PDB